Consensus on the management of inflammatory bowel disease in China in 2007

Journal of Digestive Diseases

Volumn 9, Issue 1, 2008, Pages 52-62

  Ouyang, Qin ^a   Hu, Pin Jin ^b   Qian, Jia Ming ^c   Zheng, Jia Ju ^d   Hu, Ren Wei ^a  

^a SICHUAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CEPHALOSPORIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FOLIC ACID; HERBACEOUS AGENT; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NITROIMIDAZOLE; OLSALAZINE; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ARTICLE; BARIUM ENEMA; BEHCET DISEASE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL PROTOCOL; COLITIS; COLON CANCER; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; INTESTINE INFECTION; INTESTINE TUBERCULOSIS; IRRITABLE COLON; MAINTENANCE THERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCHISTOSOMIASIS; TREATMENT INDICATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

CHINA; COLITIS, ULCERATIVE; CONSENSUS; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 38849101662     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00320.x     Document Type: Article

References (10)

1. Chinese Society of Gastroenterology of Chinese Medical Association. Suggested guidelines for the diagnosis and treatment of inflammatory bowel disease. Chin J Inter Med 2001; 2: 202-8.
2. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005; 21: 408-13.
3. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease. Controversies, Consensus, Implications Gut 2006; 55: 749-53.
4. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96: 635-43.
5. Stange EF, Travis SP, Vermeire S et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut 2006; 55 (Suppl.): I1-i5.
6. Shivananda S, Hordijk ML, Ten Kate FJ, Probert CS, Mayberry JF. Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. Scand J Gastroenterol 1991; 26: 167-73.
7. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl.): V1-16.
8. Zheng JJ, Cu XQ, Shi XH et al. Colonoscopic and histologic features of colonic Crohn's disease in Chinese patients. J Dig Dis 2007; 8: 35-41.
9. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex 2006; 71: 351-401.
10. Ouyang Q, Tandon R, Goh KL et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21: 1772-82.